Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation_20100107

Mitsubishi Tanabe Pharma Corporation patents


Recent patent applications related to Mitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe Pharma Corporation is listed as an Agent/Assignee. Note: Mitsubishi Tanabe Pharma Corporation may have other listings under different names/spellings. We're not affiliated with Mitsubishi Tanabe Pharma Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Mitsubishi Tanabe Pharma Corporation-related inventors


Rgma binding protein and use thereof

The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity arid few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa... Mitsubishi Tanabe Pharma Corporation

Rotavirus-like particle production in plants

A method of producing a rotavirus-like particle (RLP) in a plant is provided. The method comprises expressing within a host or host cell for example a plant, portion of a plant or plant cell one or more nucleic acid comprising one or more regulatory region operatively linked to a first,... Mitsubishi Tanabe Pharma Corporation

Polynucleotide construct capable of displaying fab in a cell-free translation system, and manufacturing and screening fab using same

The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding... Mitsubishi Tanabe Pharma Corporation

Organic compounds

A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.... Mitsubishi Tanabe Pharma Corporation

Human anti-il-33 neutralizing monoclonal antibody

An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies... Mitsubishi Tanabe Pharma Corporation

Agent for preventing and/or treating ophthalmologic diseases

It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone... Mitsubishi Tanabe Pharma Corporation

Novel crystalline arylalkylamine compound and process for producing the same

The present invention provides novel crystal forms of arylalkylamine compounds. Specifically, the novel crystal forms of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid have excellent stability and therefore are useful as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing the arylalkylamine compounds.... Mitsubishi Tanabe Pharma Corporation

Novel pyrrolidine compound and application as melanocortin receptor agonist

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1... Mitsubishi Tanabe Pharma Corporation

Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases

(hereinafter referred to as Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from... Mitsubishi Tanabe Pharma Corporation

Antibody-fynomer conjugates

Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and... Mitsubishi Tanabe Pharma Corporation

Aromatic heterocyclic compound

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is... Mitsubishi Tanabe Pharma Corporation

Novel disubstituted 1, 2, 4-triazine compound

or a pharmaceutically acceptable salt thereof.... Mitsubishi Tanabe Pharma Corporation

Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof

[wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.... Mitsubishi Tanabe Pharma Corporation

Medicament for suppressing malignant tumor metastasis

Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In... Mitsubishi Tanabe Pharma Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Mitsubishi Tanabe Pharma Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mitsubishi Tanabe Pharma Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###